申请人:Klaveness Jo
公开号:US20070254874A1
公开(公告)日:2007-11-01
Novel modulators of 5-HT4 receptors have been developed which have a selectivity for peripheral receptors rather than those of the central nervous systems. Theses include novel derivatives of known modulators as well as entirely novel entities. Surprisingly, the derivatised compounds of the known modulators maintain a high binding affinity to 5-HT4 receptors, despite the presence of an acidic moiety at the end of an optional chain. The entirely novel entities also exhibit good binding affinity to 5-HT4 receptors. All of the compounds of the invention have a common motif which includes a basic nitrogen moiety and an acidic moiety. The compounds of the invention, due at least in part to their high ionisation potential at physiological pH, have the unique properties of selectively for peripheral 5HT4 receptors over those of the CNS, good binding affinity, and selectively of 5HT4 receptors over other serotonin receptors.
已经开发出了5-HT4受体的新型调节剂,其选择性针对的是外周受体而非中枢神经系统受体。其中包括已知调节剂的新型衍生物以及全新的实体。令人惊讶的是,已知调节剂的衍生物化合物尽管在可选链的末端存在酸性基团,但仍保持对5-HT4受体的高结合亲和力。全新的实体也表现出良好的5-HT4受体结合亲和力。发明中的所有化合物都具有一个共同的基团,其中包括一种碱性氮基团和一种酸性基团。该发明中的化合物,至少部分原因是由于它们在生理pH值下具有高离化电位,具有选择性地作用于外周5-HT4受体而非中枢神经系统受体,具有良好的结合亲和力,并且对5-HT4受体的选择性高于其他血清素受体。